The viability of a programme for delivering aerosolized pentamidine within the patient's home setting for the secondary prophylaxis of Pneumocystis carinii pneumonia (PCP) has been explored with seven homosexual AIDS patients, the major objectives being the assessment of the safety and acceptability of the treatment and the discovery of the most suitable care setting (home, ward, outpatient clinic) for the administration of therapy. It is concluded that a domiciliary prophylaxis programme is a viable alternative.
Introduction
More than 60% of patients with the acquired immune deficiency syndrome (AIDS) develop Pneumocystis carinii pneumonia (PCP) and 30-85% of AIDS patients who survive PCP will develop recurrent PCP within 12 months'. Secondary prophylaxis for PCP is thus an important matter. Strong evidence exists that aerosolized pentamidine is an effective non-toxic treatment for acute PCpl,2 and, furthermore, the safety and efficacy of aerosolized pentamidine for the secondary prevention of PCP has been established, although despite this, it is still not licensed for the purposes of prophylaxis in the UK. Additionally, the dose, frequency and mode of delivery for achieving the most effective prophylaxis remains to be estab-Iished-:".
Adequate care of patients with progressive human immunodeficiency virus (HIV) infection can only be achieved by a patient-centred multidisciplinary approach, the roles of the various health care workers involved varying in significance at different stages of the illness's progression. The apparent efficacy of aerosolized pentamidine in the treatment of pulmonary Pneumocystis carinii infections will ensure its increasing use in patients with ARC or AIDS, but in view of the expected increase in patient numbers this would ultimately put a considerable strain on the resources of outpatient clinics and hard-pressed hospital beds. To reduce this burden and allow the patient a greater degree of choice and control over his or her circumstances the extension of this form of treatment into the patient's home is appealing. To date, extremely few individual cases of domiciliary administration of pentamidine have been reported"; the present study was designed to explore the practicality, efficacy and patient acceptability of the domiciliary approach to secondary prophylaxis with aerosolized pentamidine.
Subjects and methods
Seven male homosexual patients (six on zidovudine) who had had at least one previous episode of PCP were enrolled as suitable candidates for prophylactic treatment with aerosolized pentamidine isethionate. The initial period of assessment was 10 weeks.
A dose of 600 mg of pentamidine dissolved in 4 ml of water for injection was administered weekly through a 'life care' nebulizer mist unit driven by a portable pump ('Porta-Neb 50') or by a wall oxygen unit. The treatment was supervised and monitored by the team community nurses. At weeks 1, 5 and 10, the patients attended the outpatient clinic so that full medical review (including full haematological and biochemical assessment) could be performed in conjunction with provision of treatment, while for the other occasions, the venue (home, outpatient or ward) was agreed prior to starting the study. At each visit, the patient's blood pressure, pulse rate, temperature and weight were recorded. A checklist was completed, which included peak expiratory flow rate (PEFR) and symptoms experienced preceding and following treatment. At the end of the study, the patient was asked to complete a questionnaire which sought his or her opinion about aspects of the study. These included acceptability in terms of symptoms and convenience, preference for any particular treatment setting and why, and finally whether they would wish to continue with this form of treatment.
Results
During the initial lO-week period of study, none of the patients had any recurrence of PCP but all experienced side effects from the treatment; these included nausea, cough, wheeze and a general feeling of unwellness which might persist for a few hours. These symptoms were usually transient but were particularly severe in the case of smokers, in whom PEFR would drop by more than 20%. Acceptability was improved considerably in all patients by the use of nebulized ipratropium bromide (0.5 mg) prior to receiving pentamidine. Weight, blood pressure, temperature and pulse rate all remained within acceptable levels. There were no significant changes in any of the haematological or biochemical parameters.
Five of the patients reported a preference for home delivery, mainly to due to reasons of convenience and also as this enabled them to increase their degree of independence. One of the patients preferred the outpatient clinic area as he felt 'safer' in the knowledge of easily accessible medical back-up; this patient had experienced distressing side effects during 0141-011,68/90/ 0100IM2/$02.00/0 © 19901 The RQlYal Society) of Medicine the initial stages of treatment. The other remaining patient also opted for hospital clinic-based outpatient treatment as he did not wish his illness to be brought into the 'privacy' of his home life.
At the end of the 10-week assessment period, all patients wished to continue with some form of treatment with nebulized pentamidine, and since that time, a further seven patients have been started on a similar treatment programme. However, the regimen has since been simplified to once fortnightly dosing with a reduced pentamidine dose of 150 mg. Since the commencement of the project, there has been no proven recurrence of PCP in any of the 14 patients who have been receiving regular inhaled pentamidine (a period of more than one year).
Discussion
Two principle points emerge from the current data: (a) the safety and efficacy of nebulized pentamidine, even at the initially high dose of 600 mg weekly, in the prevention of recurrent PCP has been made clear. (b) A domiciliary-based treatment service is a practical option. Other important points to emerge are that smokers may experience more in the way of adverse symptoms than non-smokers, and that pre-treatment with nebulized ipratropium bromide may improve patient acceptability.
We conclude that it is possible that morbidity and mortality in AIDS patients related to recurrent PCP could be reduced by the use of prophylactic nebulized pentamidine treatment, and that a domiciliary approach to treatment provision may improve the quality of the patients' lives.
